NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the
“
Company” or “
NurExone”), a
biopharmaceutical company developing biologically-guided exosome
therapy for patients with traumatic spinal cord injuries, is
pleased to announce that it has closed a non-brokered private
placement (the “
Private Placement”). An aggregate
of 7,091,993 units of the Company (each a “
Unit”)
were issued and sold under the Private Placement at a price of
CAD$0.28 per Unit for aggregate proceeds of CAD$1,985,758.04.
Each Unit consists of (i) one common share in
the capital of the Company (each, a “Common
Share”), and (ii) one Common Share purchase warrant (each,
a “Warrant”). Each Warrant entitles the holder
thereof to purchase one Common Share at a price of CAD$0.35 per
Common Share for a period of 36 months from the closing of the
Private Placement.
The Warrants are subject to accelerated
expiration whereby if the daily volume weighted average trading
price of the Common Shares on the TSX Venture Exchange
(“TSXV”) for any period of 20 consecutive trading
days equals or exceeds CAD$0.80, the Company may, upon providing
written notice to the holders of the Warrants (the
“Acceleration Notice”), accelerate the expiry date
of the Warrants to a date not less than 30 days following the date
of the Acceleration Notice. If the Warrants are not exercised by
the applicable accelerated expiry date, the Warrants will expire
and be of no further force or effect.
All securities issued under the Private
Placement are subject to a statutory hold period of four months and
one day from the closing of the Private Placement. The Private
Placement is subject to final approval of the TSXV. The Company
intends to use the proceeds of the Private Placement for working
capital purposes.
Dr. Lior Shaltiel, NurExone CEO stated: “We are
truly honored to receive the support of our investors, who have
placed their trust in NurExone’s technology and exceptional team.
Despite the challenging times in the markets, the fact that we have
successfully raised a significant investment demonstrates the
strong confidence and trust that the investment community and
bio-tech professionals have in NurExone. As we embark on the
journey of 2024, we remain committed to advancing the development
of our unique assets and eagerly anticipate brighter days
ahead.”
“The Company intends to use the proceeds of the
Private Placement for advancing the development activities of the
Company's assets, with a particular focus on progressing towards
the clinical phase. Additionally, we plan to leverage these funds
to expand the company's intellectual property portfolio and support
various general corporate purposes,” said Eran Ovadya, CFO of
NurExone.
This news release does not constitute an offer
to sell or a solicitation of an offer to buy any of the securities
described in this news release in the United States. Such
securities have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities laws, and,
accordingly, may not be offered or sold within the United States,
or to or for the account or benefit of persons in the United States
or “U.S. Persons”, as such term is defined in Regulation S
promulgated under the U.S. Securities Act, unless registered under
the U.S. Securities Act and applicable state securities laws or
pursuant to an exemption from such registration requirements.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company developing a platform for
biologically-guided ExoTherapy using exosomes as a next generation
drug delivery system. The Company’s first product, ExoPTEN, is
aimed at neural regeneration and recovery in patients who have
suffered acute spinal cord injury. Notably, ExoPTEN has received
Orphan Drug Designation by the FDA highlighting its potential
significance for these patients. The Company holds an exclusive
worldwide license from the Technion and Tel Aviv University for the
development and commercialization of the technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation -
CanadaPhone: +1 905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation -
GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
“forward-looking statements”, that reflect the Company’s current
expectations and projections about its future results. Wherever
possible, words such as “may”, “will”, “should”, “could”, “expect”,
“plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or
“potential” or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the use of proceeds of the Private Placement and the receipt of
final approval of the TSXV of the Private Placement. These
statements reflect management’s current beliefs and are based on
information currently available to management as at the date
hereof.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
including our estimated future expenditures; the general business
and economic conditions of the industries and countries in which we
operate; the market conditions; inflation will remain stable; and
that the results of our studies reflect results that can be
extrapolated.
Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks related to the Company’s early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company’s
intellectual property, dependence on the Company’s strategic
partners and the risks discussed under the heading “Risk Factors”
on pages 29 to 36 of the Company’s Annual Information Form dated
March 30, 2023, a copy of which is available under the Company’s
SEDAR+ profile at www.sedarplus.ca. These factors should be
considered carefully and readers should not place undue reliance on
the forward-looking statements. Although the forward-looking
statements contained in this press release are based upon what
management believes to be reasonable assumptions, the Company
cannot assure readers that actual results will be consistent with
these forward-looking statements. These forward-looking statements
are made as of the date of this press release, and the Company
assumes no obligation to update or revise them to reflect new
events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Nurexone Biologic (TSXV:NRX)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Nurexone Biologic (TSXV:NRX)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024